Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Evogene (EVGN) over the last 10 years, with Q3 2025 value amounting to $12000.0.

  • Evogene's Gains from Investment Securities fell 8736.84% to $12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $93000.0, marking a year-over-year decrease of 8573.62%. This contributed to the annual value of $2.3 million for FY2024, which is 877307.69% up from last year.
  • Latest data reveals that Evogene reported Gains from Investment Securities of $12000.0 as of Q3 2025, which was down 8736.84% from -$3000.0 recorded in Q2 2025.
  • In the past 5 years, Evogene's Gains from Investment Securities ranged from a high of $519000.0 in Q1 2024 and a low of -$102000.0 during Q4 2021
  • Moreover, its 5-year median value for Gains from Investment Securities was -$5000.0 (2022), whereas its average is $26941.2.
  • Per our database at Business Quant, Evogene's Gains from Investment Securities crashed by 160000.0% in 2021 and then soared by 209615.38% in 2024.
  • Evogene's Gains from Investment Securities (Quarter) stood at -$102000.0 in 2021, then surged by 94.12% to -$6000.0 in 2022, then plummeted by 166.67% to -$16000.0 in 2023, then soared by 31.25% to -$11000.0 in 2024, then soared by 209.09% to $12000.0 in 2025.
  • Its Gains from Investment Securities stands at $12000.0 for Q3 2025, versus -$3000.0 for Q2 2025 and -$11000.0 for Q4 2024.